The QUEST trial (Chinese Clinical Trials Registry Number ChiCTR1900021929), aimed to investigate the effects of qiliqiangxin, a Traditional Chinese Medicine formulation, in patients with Heart Failure with Reduced Ejection Fraction (HFrEF). A total of 3110 HFrEF patients were randomly assigned to receive qiliqiangxin (n=1555) or a placebo (n=1555). The primary measure of efficacy was a composite event involving cardiovascular (CV) death and re-hospitalization due to deteriorating HF. After a median follow-up period of 18.3 months, the qiliqiangxin group exhibited a 25% occurrence of the primary outcome event, while the placebo group recorded a 30% incidence of the same outcome event.
Learn more about the interesting studies presented at ESC Congress 2023.
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.
